We are focused on applying our novel technologies to support partner development efforts for their own proprietary programs and compounds.
- Dry Powder Delivery: Technosphere® Technology:
We have evaluated this versatile pulmonary drug delivery platform across multiple therapeutic areas, including diabetes, metabolism, osteoporosis and pain.
For companies interested in exploring the feasibility of a Technosphere formulation using their own active pharmaceutical ingredient (API), MannKind is able to prepare and characterize API/Technosphere formulations utilizing relevant PK/PD models, thereby providing a low risk non-clinical proof of principle, often within 6 months.
- Inhalers: Device Technology: We have created an innovative line of patient-focused, breath-powered dry powder inhalers offering both high performance and cost-effectiveness.
- Inhalation Profiling: BLUHALE® is a wireless microphone-based technology adapted onto MannKind's dry powder delivery systems to characterize patient inhalation.